Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Micromet, Inc.

http://www.micromet.de

Latest From Micromet, Inc.

SparingVision Eyes CRISPR Promise With Intellia Ocular Pact

The French biotech has managed to bag a blue-chip partner to advance its ambitions to be the leading company in the ocular genomic medicine space, getting access to Intellia's CRISPR/Cas9 technology.

Ophthalmic Gene Therapy

Stock Watch: Unnatural Selection In Clinical Trials

Patient selection is held out as the Achilles heel of clinical trial success. But a surprise and fortunate finding in Pfizer’s gene therapy trial has already resulted in tightened recruitment criteria, thanks to genetic analysis.

Stock Watch Clinical Trials

First Results From Editas CRISPR Eye Therapy Underwhelm Investors

While rivals Intellia impressed with their first in vivo CRISPR gene-editing data, Editas’s first results in just two patients are not enough to convince investors.

Commercial Clinical Trials

136 Years And Counting: Boehringer Ingelheim Sees Advantage In Private Structure

The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.

Companies Business Strategies
See All

Company Information

  • Other Names / Subsidiaries
    • CancerVax Corporation
UsernamePublicRestriction

Register